MacuCLEAR, Inc. And Mystic Successfully Complete Phase Ib Clinical Trial For Macular Degeneration – Medial News Today

//MacuCLEAR, Inc. And Mystic Successfully Complete Phase Ib Clinical Trial For Macular Degeneration – Medial News Today

MacuCLEAR, Inc. And Mystic Successfully Complete Phase Ib Clinical Trial For Macular Degeneration – Medial News Today

MacuCLEAR, Inc. (“MacuCLEAR”) and Mystic Pharmaceuticals, Inc., (“Mystic”) announced preliminary successful results of a Phase Ib Clinical Trial for the treatment and prevention of the progression of Age Related Macular Degeneration (AMD). The preliminary results indicated that MacuCLEAR’s MC-1101 drug is safe and well tolerated by study participants, and has a biological effect on blood flow in the back of the retina. Mystic’s VersiDoser™ ophthalmic delivery system was used by trial participants to self-administer MC-1101 to the front of the eye during the trial. The study included Proof Of Concept (“POC”) indicators. A key finding of the study was the successful migration of the drug to the back of the eye.

Read the Full Article
2017-05-23T18:33:43+00:00 October 11, 2009|Categories: In the News|0 Comments